The Role and Risks of Systemic Corticosteroids in Atopic Dermatitis: An Expert Consensus
Main Article Content
Keywords
systemic corticosteroids, safety, short-term, long-term, adverse effects, advanced systemic therapies, eczema, skin disease
Abstract
Background Atopic dermatitis (AD) is a chronic inflammatory disease affecting millions worldwide. Despite strong recommendations from leading dermatology organizations discouraging routine use of systemic corticosteroids (SCS) in AD, they remain frequently prescribed. This expert consensus provides evidence-based recommendations on the role of SCS in the management of AD.
Methods A comprehensive literature search was completed using combination of keywords “atopic dermatitis,” “systemic corticosteroids,” “adverse effects,” “short-term,” “long-term,” and “alternative therapies”. A panel of 9 dermatologists with substantial expertise in management of AD reviewed eligible articles using Strength of Recommendation Taxonomy (SORT) criteria and developed consensus statements. A modified Delphi process was used to approve each statement, and a strength of recommendation was assigned.
Results The literature search produced 500 articles, of which 27 met screening criteria for inclusion. The expert panel unanimously voted to adopt 11 consensus statements and recommendations: eight with strength of “A” and three with strength of “C”.
Conclusion This expert consensus defines evidence-based thresholds for short- and long-term systemic SCS use in AD, highlights their significant safety risks, and affirms that any SCS exposure constitutes a systemic therapy trial, supporting prompt transition to advanced systemic treatments.
References
doi:10.25251/skin.8.supp.448
2. Davis DMR, Drucker AM, Alikhan A, et al. American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86(6):1335-1336.e18. doi:10.1016/j.jaad.2022.01.009
3. AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice
Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2024;132(3):274-312. doi:10.1016/j.anai.2023.11.009
4. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904-1926.
doi:10.1111/jdv.18429
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.